TP53 and neoplasm: However, its overall mutation frequency of approximately 25% in breast cancer [2,3] is less than the mean percentage of TP53 mutations in cancer (approximately 50%) [2], suggesting that other mechanisms may be responsible for the disruption of this critical tumour suppressor and its pathway in breast cancer.